GlassScriptPhysician profile
Katrina Miller
NPI 1477154367
$4,184.41
in general payments reported to CMS, 2019-2025
43 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $818 · 2023: $620 · 2024: $1,291 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,960 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,959.60 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $669.12 | 2022-2025 | Rexulti |
| Abbvie INC. | $399.82 | 2021-2025 | |
| Novo Nordisk INC | $330.62 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $312.42 | 2021-2025 | Farxiga, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $264.24 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $253.81 | 2021-2024 | Trelegy Ellipta |
| Astellas Pharma US INC | $183.76 | 2025 | Veozah |
| Pfizer INC. | $148.08 | 2021-2024 | |
| Amgen INC. | $129.30 | 2022-2025 | Repatha, Repatha, Otezla |
| Sumitomo Pharma America, INC. | $125.48 | 2023-2024 | Gemtesa |
| Vanda Pharmaceuticals INC. | $99.30 | 2024 | Fanapt |
| Lundbeck LLC | $77.68 | 2024-2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $75.96 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $74.91 | 2024-2025 | Austedo Xr, Austedo Xr |
| Insulet Corporation | $74.61 | 2022-2023 | Omnipod |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.